Comparative Costs to Medicare and Medicare Beneficiaries of Alternative AF Stroke Risk Reduction Strategies

References

• Go AS, Hylek EM, Phillips KA. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–2375. doi:10.1001/jama.285.18.2370
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ. Secular trends in incidence of atrial fibrillation in Olmsted county, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–125. doi:10.1161/CIRCULATIONAHA.105.595140
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–1147. doi:10.1016/j.amjcard.2013.05.063
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hammill BG, Sinner MF. Incidence and prevalence of atrial fibrillation and associated mortality among medicare beneficiaries, 1993–2007. Circ Cardiovasc Qual Outcomes. 2012;5:85–93. doi:10.1161/CIRCOUTCOMES.111.962688
   PubMed Web of Science ®Google Scholar
• Al-Kawaz M, Omran SS, Parikh NS, Elkind MSV, Soliman EZ, Kamel H. Comparative risks of ischemic stroke in atrial flutter versus atrial fibrillation. J Stroke Cerebrovasc Dis. 2018;27:839–844. doi:10.1016/j.jstrokecerebrovasdis.2017.10.025
   PubMed Web of Science ®Google Scholar
• Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348–356. doi:10.1111/j.1524-4733.2006.00124.x
   PubMed Web of Science ®Google Scholar
• Lee WC, Lamas GA, Balu S, Spalding J, Wang Q, Pashos CL. Direct treatment cost of atrial fibrillation in the elderly American population: a medicare perspective. J Med Econ. 2008;11:281–298. doi:10.3111/13696990802063425
   PubMedGoogle Scholar
• Kimmel SE. The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (in-range) study. Arch Intern Med. 2007;167:229–235. doi:10.1001/archinte.167.3.229
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S; On behalf of RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. doi:10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J; On behalf of ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. doi:10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ; On behalf of ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. doi:10.1056/NEJMoa1107039
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. doi:10.1056/NEJMoa1310907
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Alexander GC. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5 doi:10.1161/JAHA.115.003074
   Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American heart association task force on clinical Practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2019;74(1):104–132. doi:10.1016/j.jacc.2019.01.011
   PubMed Web of Science ®Google Scholar
• Boston Scientific Corp, Marlborough MA. WATCHMANTM [package insert]; 2015. Available from: http://www.bostonscientific.com/content/dam/Manuals/us/current-rev-en/90746221-01C_Watchman%20Device_DFU_en-US_s.pdf. Accessed November 30, 2023.
   Google Scholar
• Reddy VY, Sievert H, Halperin J; on behalf of PROTECT AF steering committee and investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation, a randomized clinical trial. JAMA. 2014;312:1988–1998. doi:10.1001/jama.2014.15192
   PubMed Web of Science ®Google Scholar
• Holmes DR, Kar S, Price MJ. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy – the PREVAIL trial. J Am Coll Cardiol. 2014;64:1–12. doi:10.1016/j.jacc.2014.04.029
   PubMed Web of Science ®Google Scholar
• Reddy VY, Doshi SK, Kar S. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964–2975. doi:10.1016/j.jacc.2017.10.021
   PubMed Web of Science ®Google Scholar
• Turagam MK, Osmancik P, Neuzil P, Dukkipati SR, Reddy VY. Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials. J Am Coll Cardiol. 2020;76:2795–2797. doi:10.1016/j.jacc.2020.08.089
   PubMed Web of Science ®Google Scholar
• Feinberg WM, Blackshear JL, Laupacis A. Prevalence, age distribution, and gender of patients with atrial fibrillation. Anal Implic Arch Intern Med. 1995;155(5):469–473. doi:10.1001/archinte.1995.00430050045005
   Google Scholar
• Cubanski J, Neuman T, Damico A, Smith KE. Medicare beneficiaries’ out-of-pocket health care spending as a share of income now and projections for the future. Available from: https://www.kff.org/medicare/report/medicare-beneficiaries-out-of-pocket-health-care-spending-as-a-share-of-income-now-and-projections-for-the-future/. Accessed 23 December 2023.
   Google Scholar
• Noel-Miller C. Medicare Beneficiaries’ Out-of-Pocket Spending for Health Care. AARP Public Policy Institute. Available from: https://www.aarp.org/content/dam/aarp/research/public_policy_institute/health/medicmed-beneficiaries-out-of-pocket-spending-AARP-ppi-health.pdf. Accessed November 30, 2023.
   Google Scholar
• Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Beard SM, Holmes DR. Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J Am Coll Cardiol. 2015;66:2728–2739. doi:10.1016/j.jacc.2015.09.084
   PubMed Web of Science ®Google Scholar
• Reddy VY, Akehurst RL, Gavaghan MB, Amorosi SL, Holmes JDR. Cost-effectiveness of left atrial appendage closure for stroke reduction in atrial fibrillation: analysis of pooled, 5-year, long-term data. J Am Heart Assoc. 2019;8(13):e011577. doi:10.1161/JAHA.118.011577
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Bridgers SL, James KE. on behalf of the veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406–1412. doi:10.1056/NEJM199211123272002
   PubMed Web of Science ®Google Scholar
• Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators*. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1501–1511.
   Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349–355. doi:10.1016/0735-1097(91)90585-W
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867. doi:10.7326/0003-4819-146-12-200706190-00007
   PubMed Web of Science ®Google Scholar
• Freeman JV, Zhu RP, Owens DK. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1–11. doi:10.7326/0003-4819-154-1-201101040-00289
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138:1093–1100. doi:10.1378/chest.10-0134
   PubMed Web of Science ®Google Scholar
• Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire community stroke project. Stroke. 1993;24:796–800. doi:10.1161/01.STR.24.6.796
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-0
   PubMed Web of Science ®Google Scholar
• Alkhouli M, Busu T, Shah K, Osman M, Alqahtani F, Raybuck B. Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis. JACC Clin Electrophysiol. 2018;4(12):1629–1637. doi:10.1016/j.jacep.2018.09.007
   PubMedGoogle Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final Results Circ. 1991;84:527–539.
   Google Scholar
• Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation, the Copenhagen AFASAK study. Lancet. 1989;8631:175–178. doi:10.1016/S0140-6736(89)91200-2
   Google Scholar
• Cipriano LE, Steinberg ML, Gazelle GS, Gonzalez RG. Comparing and predicting the costs and outcomes of patients with major and minor stroke using the Boston Acute Stroke Imaging Scale neuroimaging classification system. Am J Neuroradiol. 2009;30(703):709. doi:10.3174/ajnr.A1441
   Google Scholar
• Mercaldi CJ, Sui K, Sander SD. Long term costs of ischemic stroke and major bleeding events among medicare patients with nonvalvular atrial fibrillation. Cardiol Res Pract. 2012;2012:1–13. doi:10.1155/2012/645469
   Google Scholar
• Caro JJ, Huybrechts FK. Stroke treatment economic model (STEM): predicting long term costs from functional status. Stroke. 1999;30:2574–2579. doi:10.1161/01.STR.30.12.2574
   PubMed Web of Science ®Google Scholar
• Financial G, Inc. Compare Long Term Care Costs Across the United States. Available from: https://www.genworth.com/about-us/industry-expertise/cost-of-care.html. Accessed November 30, 2023.
   Google Scholar
• FY 2023 IPPS Final Rule Home Page | CMS. Available from: https://www.cms.gov/medicare/acute-inpatient-pps/fy-2023-ipps-final-rule-home-page. Accessed March 2, 2023.
   Google Scholar
• 2023 Medicare Parts A & B premiums and deductibles 2023 Medicare Part D income-related monthly adjustment amounts | CMS. Available from: https://www.medicare.gov/basics/costs/medicare-costs. Accessed March 2, 2023.
   Google Scholar
• The Coding Institute. CPT® Code Lookup. Available from: https://www.supercoder.com/cpt-codes-range. Accessed November 30, 2023.
   Google Scholar
• America DMD. Drug pricing database.
   Google Scholar
• Lee B, Chatterjee C, Higgins MJ. Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry. NBER Work Pap; 2011:17188. Available from: http://www.nber.org/papers/w17188. Accessed November 30, 2023.
   Google Scholar
• Inpatient Rehabilitation Facility PPS | CMS. Available from: https://www.cms.gov/medicare/medicare-fee-for-service-payment/inpatientrehabfacpps. Accessed March 2, 2023.
   Google Scholar
• Costs. Medicare. Available from: https://www.medicare.gov/basics/costs/medicare-costs. Accessed March 2, 2023.
   Google Scholar
• Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillation. Am Heart J. 2009;157:1064–1073.
   PubMed Web of Science ®Google Scholar
• Reaves EL, Found HJKF. Medicaid and long-term services and supports: a Primer; 2015. Available from: https://www.kff.org/medicaid/report/medicaid-and-long-term-services-and-supports-a-primer/. Accessed November 30, 2023.
   Google Scholar
• Brook RH, Ware JE, Rogers WH The effect of coinsurance on the health of adults; 1984. Available form: https://www.rand.org/pubs/reports/R3055.html. Accessed November 30, 2023.
   Google Scholar
• Brot-Goldberg ZC, Chandra A, Handel BR, Kolstad JT. What does a deductible do? The impact of cost-sharing on health care prices, quantities, and spending dynamics. Natl Bur Econ Res.132.
   Google Scholar
• Heckman BW, Mathew AR, Carpenter MJ. Treatment burden and treatment fatigue as barriers to health. Curr Opin Psychol. 2015;5:31–36.
   PubMed Web of Science ®Google Scholar
• Lang K, Bozkaya D, Patel AA. Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis. BMC Health Serv Res. 2014;14(329).
   Google Scholar
• Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74:1237–1244.
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Kourbeti IS, Poulou LS, Vlachogeorgos GS, Mylonakis E. Medicare part D prescribing for direct oral anticoagulants in the United States: cost, use and the “rubber effect. PLoS One. 2018;13:e0198674. doi:10.1371/journal.pone.0198674.
   PubMed Web of Science ®Google Scholar
• Freeman JV, Varosy P, Price MJ. The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol. 2020;75:1503–1518.
   PubMed Web of Science ®Google Scholar
• Kar S, Doshi SK, Sadhu A. Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation. 2021;143:1754–1762.
   PubMed Web of Science ®Google Scholar
• Haldorsen E. The right treatment to the right patient at the right time. Occup Env Med. 2003;60:235–236.
   PubMed Web of Science ®Google Scholar